Table 3b.
Multivariable risk factors for resolution of insulin resistance among HIV-infected adolescents during follow-up (N=87) (including waist circumference)
| Univariable Hazard Ratio (95% CI) | P-value | Multivariable Hazard Ratio (95% CI) | P-value | |
|---|---|---|---|---|
| Female Sex (reference = Male) | 0.45 (0.24, 0.85) | 0.01 | 0.32 (0.16, 0.67) | 0.002 |
| Race/ethnicity (reference = White/Multi/Other Non-Hispanic) | 0.40 | 0.73 | ||
| Black Non-Hispanic | 0.45 (0.16, 1.29) | 0.64 (0.20, 2.04) | ||
| Hispanic | 0.45 (0.14, 1.52) | 0.60 (0.16, 2.30) | ||
| Tanner stage (reference = 1) | 0.85 | 0.81 | ||
| 2 | 0.48 (0.13, 1.80) | 0.68 (0.17, 2.82) | ||
| 3 | 0.65 (0.19, 2.27) | 0.50 (0.10, 2.53) | ||
| 4 | 0.78 (0.23, 2.63) | 0.78 (0.18, 3.28) | ||
| 5 | 0.77 (0.28, 2.11) | 0.97 (0.19, 4.92) | ||
| Waist circumference (for every cm increase) | 0.98 (0.96, 1.00) | 0.06 | 0.98 (0.95, 1.00) | 0.09 |
| CD4 count (cells/mm3, reference = > 500 cells/mm3) | 0.58 | 0.37 | ||
| < 350 | 0.82 (0.19, 3.43) | 1.04 (0.24, 4.64) | ||
| 351–500 | 1.65 (0.64, 4.27) | 2.16 (0.73, 6.33) | ||
| Didanosine: Ever up to end of follow-up (reference = never use) | 1.51 (0.74, 3.07) | 0.25 | 1.64 (0.59, 4.51) | 0.34 |
| Lopinavir/ritonavir: Current (reference = no current use) | 1.88 (0.98, 3.60) | 0.06 | 2.42 (1.17, 4.99) | 0.02 |
CI: confidence interval